key: cord-0879804-3dux41yg
authors: Martiniano, Bello
title: Prediction of potential inhibitors of the dimeric SARS-CoV2 main proteinase through the MM/GBSA approach
date: 2020-09-24
journal: J Mol Graph Model
DOI: 10.1016/j.jmgm.2020.107762
sha: d5049245b6cd4b20a158562246884b62ade4f502
doc_id: 879804
cord_uid: 3dux41yg

Since the emergence of SARS-CoV2, to date, no effective antiviral drug has been approved to treat the disease, and no vaccine against SARS-CoV2 is available. Under this scenario, the combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, has attracted attention since they have been previously employed against the SARS-CoV main proteinase (M(pro)) and exhibited some signs of effectiveness. Recently, the 3D structure of SARS-CoV2 M(pro) was constructed based on the monomeric SARS-CoV M(pro) and employed to identify potential approved small inhibitors against SARS-CoV2 M(pro), allowing the selection of 15 drugs among 1903 approved drugs to be employed. In this study, we performed docking of these 15 approved drugs against the recently solved X-ray crystallography structure of SARS-CoV2 M(pro) in the monomeric and dimeric states; the latter is the functional state that was determined in a biological context, and these were submitted to molecular dynamics (MD) simulations coupled with the molecular mechanics generalized Born surface area (MM/GBSA) approach to obtain insight into the inhibitory activity of these compounds. Similar studies were performed with lopinavir and ritonavir coupled to monomeric and dimeric SARS-CoV M(pro) and SARS-CoV2 M(pro) to compare the inhibitory differences. Our study provides the structural and energetic basis of the inhibitory properties of lopinavir and ritonavir on SARS-CoV M(pro) and SARS-CoV2 M(pro), allowing us to identify two FDA-approved drugs that can be used against SARS-CoV2 M(pro). This study also demonstrated that drug discovery requires the dimeric state to obtain good results.

In December 2019, another outbreak of acute respiratory disease caused by a novel coronavirus (CoV) was reported in Wuhan, China [1, 2] . Analysis of the complete genome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) demonstrated that it belongs to betacoronavirus, but it is different from severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East Respiratory coronavirus (MERS-CoV), which caused previous epidemics [1] . This new disease was named coronavirus disease 2019 , previously known as novel coronavirus [2019-nCoV] , by the World Health Organization. COVID-19 was first reported in China, and it has now spread quickly to distant nations, including France and the USA. The number of cases within and outside China are increasing abruptly, and no drug has proved to be effective. Therefore, it is crucial to discover and develop drugs to treat the disease. An alternative treatment for COVID-19 is the combination of two HIV-1 protease inhibitors, lopinavir and ritonavir, which was an effective therapy previously used against SARS-CoV [3] . Previous theoretical studies demonstrated that lopinavir and ritonavir form stable complexes with the SARS-CoV main proteinase (SARS-CoV M pro ), with similar affinity [4] . Similar to SARS- highlighting nelfinavir as a potential inhibitor against SARS-CoV2 M pro [5] . Using X-ray crystallography, the structure of SARS-CoV2 M pro has recently been solved in complex with the inhibitor N3 (PDB ID: 6LU7), revealing that its structural topology is similar to that of other CoV proteinases. SARS-CoV2 M pro is built in a homodimer conformation, formed of three domains: domains 1 (residues 8-101) and 2 (residues 102-184) are βbarrels, and domain 3 (residues 201-306) comprises mainly α-helices, and it is connected to domain 2 by an elongated loop region (residues 185-200). The substrate-binding site of J o u r n a l P r e -p r o o f SARS-CoV2 M pro is situated in a cleft between domain 1 and domain 2. Inhibitor N3 was developed using theoretical methods and it can specifically inhibit M pro from multiple coronaviruses, including SARS-CoV, SARS-CoV2 and MERS-CoV [6] [7] [8] [9] [10] [11] . Inhibitor N3 is stabilized at the substrate binding site in an extended conformation by conserved residues (H41 and C145) involved in the catalytic activity of the enzyme, in a similar manner to that observed for other CoV proteinases [4] . The backbone atoms of inhibitor form an antiparallel sheet with some residues of the long strand (residues 155-168), and with residues 189-191 of the loop that connects domain 2 to domain 3.

Proteases are typical targets for drug development because of their recognized enzymatic mechanism, however, many new potential drugs have been ineffective either because of a lack of ligand specificity or because of our incomplete understanding of the conformational state under a biological context of the targeted protease [12] . In order to successfully develop or identify new protease inhibitors, it is necessary to understand important structural features of the protease functions to expand the platform of inhibitor development. Although previous studies have considered the monomeric state of SARS-CoV M pro or SARS-CoV2 M pro to search for new inhibitors [5, 13] or to understand the molecular basis of inhibitor recognition [4] , kinetic studies have indicated that the active form of the SARS CoV main proteinase corresponds to a homodimer [14] , suggesting significant conformational differences between the monomer and dimeric states and indicating that drug discovery combining docking and MD simulations should be performed using the homodimeric conformation instead of the monomer. In the present research, the crystallographic dimeric structure of SARS-CoV2 M pro , the first released structure of this enzyme available at the protein data bank (PDB ID: 6LU7), was docked against 15 Food and Drug Administration (FDA) approved drugs identified in a previous study [5] and then submitted to MD simulations coupled to the MM/GBSA approach to dissect the structural and energetic basis of molecular recognition considering the monomeric and dimeric states. In addition, comparative analysis was performed for dimeric SARS-CoV2 M pro and SARS-CoV M pro coupling to lopinavir and ritonavir, which have been shown to be an effective therapy against SARS-CoV M pro . (DB01601) and ritonavir (DB00503), were downloaded from DrugBank version 5.0 [15] and optimized at the AM1 level employing Gaussian 09W [16] . The X-ray crystallography structures of SARS-CoV2 M pro (PDB ID: 6LU7, 2.16 Å) and SARS-CoV M pro (PDB ID: 2GX4, 1.93 Å) were used to construct the protein-ligand complexes. PDB structures employed for this research were selected based on their availability (PDB ID: 6LU7, 2.16 Å), high resolution, without mutations and missing residues.

The seventeen FDA-approved small drugs were docked on monomeric and dimeric SARS-CoV2 M pro using AutoDock Tools 1.5.6 and AutoDock 4.2 programs [17] . Lopinavir and ritonavir were docked on monomeric and dimeric SARS-CoV M pro . In the previous docking calculation, hydrogen atoms were added to the ligand, and protein atoms and Kollman and Gasteiger partial charges were assigned for the receptor and ligand, respectively. The grid box was centered on the substrate-binding site of each monomeric subunit with grid points in the x, y and z of 70 x 70 x 70 Å, respectively, with a grid spacing of 0.375 Å. The ligand place was optimized using a Lamarckian genetic algorithm. The protein-ligand conformation with the lowest binding energies was selected as the initial conformer to start MD simulations. The compounds reached the substrate binding site of SARS-CoV M pro and J o u r n a l P r e -p r o o f SARS-CoV2 M pro , obtaining a root-mean-square deviation (RMSD) of 0.5 Å to 2.0 Å with respect to the co-crystallized compound. About 20 runs were run for each compound and 30 binding poses of the ligand were obtained between compounds and receptor. The docking protocol was validated by reproducing the experimental binding mode of inhibitor N3 and TG-0205221 (scheme) on SARS-CoV2 M pro (PDB ID: 6LU7) and SARS-CoV M pro (PDB ID: 2GX4), respectively. By using this methodology, we identified that our docking methodology was able to reproduce the experimental binding mode of both compounds with RMSD values lower than 1.0 Å.

MD simulations were carried out using the AMBER16 package [18] and the ff14SB force field [19] . The force field of ligands was performed considering AM1-BCC atomic charges and the general Amber force field (GAFF) [20] . Each complex generated through docking was neutralized with 0.10 M NaCl and then solvated using the TIP3P water model [21] in a dodecadic box of 12.0 Å. Previously, MD simulations for each complex were minimized through 1000 steps for the steepest descent and 3000 steps for the conjugate gradient. Then, the systems were heated through 200 ps, the density was equilibrated through 200 ps, and finally, the systems were equilibrated by 600 ps of constant pressure equilibration at 310 K.

Once the systems were equilibrated, MD simulations were run for 100 ns with triplicate experiments using an NPT ensemble at 310 K. The electrostatic forces were described by the particle mesh Ewald method [22] , and a 10 Å cutoff was chosen for the van der Waals interactions. The SHAKE algorithm [23] was used to constrain bond lengths at their equilibrium values. Temperature and pressure were maintained using the weak-coupling algorithm [24] . The results were analyzed using AmberTools16. Images were built using PyMOL [25] .

The MM/GBSA [26, 27] method was employed to calculate the binding free energy (∆G bind ) values between the receptor and ligand and to calculate per-residue decomposition analysis.

To this end, 500 snapshots at time intervals of 100 ps were selected over the equilibrated J o u r n a l P r e -p r o o f time, removing all counterions and water molecules with a salt concentration of 0.10 M [28] . ∆G bind and per-residue decomposition calculations were determined as described elsewhere [29] , and the ∆G bind values represent the average values of triplicate simulation experiments. Similar experiments were performed using compounds with known experimental affinity to SARS-CoV2 M pro or SARS-CoV M pro to validate the ability of MM/GBSA approach to reproduce the experimental binding affinity trend. We observed that the approach was able to reproduce the experimental tendency previously observed for two inhibitors (Chloroquine and niclosamide) of SARS-CoV2 M pro [30] , for which niclosamide showed higher affinity for SARS-CoV2 M pro in comparison to chloroquine (supplementary material, table S1). Similarly, TG-0205221, a SARS-CoV M pro inhibitor, showed a higher affinity for SARS-Cov M pro (supplementary material, table S1) in comparison to lopinavir (table 2), in line with experimental reports [31, 32] .

Docking studies between ligands and SARS-CoV2 M pro showed that all ligands: 

MD simulations showed that ritonavir lost interactions with the catalytic site of SARS-CoV2, whereas lopinavir maintained the interactions with the catalytic site (Fig. 2E) . (Figs. 3 and 7) revealed that the repositioned compounds were better stabilized in the dimeric state than in the monomeric state. In addition, only in the complexes using the dimeric system, the presence of interactions with conserved residues (H41 and C145) involved in the catalytic activity was observed [33] .

MD simulations showed that lopinavir at subunits 1 ( ∆G bind values for the ligands coupled on the first subunit of dimeric SARS-CoV2 M pro show the following tendency: perampanel > lopinavir > praziquantel > ritonavir > ofloxacin > azelastine > zopiclone > eszopiclone > fenoterol > pitavastatin> nelfinavir = celecoxib > sofosbuvir > ondansetron > naftazone. The ligands coupled at the second subunit showed the following order: nelfinavir > lopinavir > praziquantel > perampanel > azelastine > ritonavir > eszopiclone > fenoterol > ondansetron > pitavastatin> zopiclone > sofosbuvir > celecoxib > lemborexant > indomethacin > naftazone (table 2) . Based on this analysis, it is evident that perampanel, and praziquantel can be proposed as anti-COVID-19 clinical drugs, whereas nelfinavir could also exhibit moderate activities against COVID-19.

Perampanel is a drug currently employed in epilepsy, with an innovative mechanism of action through AMPA ([2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl) propanoic acid) glutamate receptors. Praziquantel is an anthelmintic drug used to treat several sorts of parasitic worm infections, and nelfinavir is a strong HIV1 protease inhibitor used with other antiviral medications to treat HIV. Interestingly, perampanel and praziquantel also exhibit a similar affinity to lopinavir and a higher affinity than ritonavir, both known inhibitors of SARS-CoV M pro [3] . A comparison of the ∆G bind values of lopinavir and ritonavir on dimeric SARS-CoV M pro versus SARS-CoV2 M pro indicated that these compounds exhibit a higher affinity for dimeric SARS-CoV2 M pro than for SARS-CoV2 M pro . In addition, a comparison between the monomeric versus dimeric SARS-CoV2 M pro and SARS-CoV M pro systems shows that although the employment of the monomeric system allowed us to identify perampanel and lopinavir as good inhibitors of SARS-CoV2, it did not permit to J o u r n a l P r e -p r o o f the identification with praziquantel nelfinavir and ritonavir, highlighting the suitability of employing the dimeric system for drug discovery. As observed for the complex between perampanel and monomeric SARS-CoV2 M pro (table   3) , N142, G143, S144 and C145, together with M165, contributed the most to the ∆G bind value (table 2) on both subunits of dimeric SARS-CoV2 M pro (table 5) . For praziquantel, the energetic contribution of M49 was only observed for one of the subunits, whereas participation of H41 and M165 was observed for both subunits, and as observed for perampanel, in which N142, G143, S144, C145 and M165 contributed importantly to the J o u r n a l P r e -p r o o f ∆G bind value (table 2) . For nelfinavir, the participation of H41, M49 and M165 was seen only in one of the subunits, the one with the higher affinity (table 2) 303), they are in close distance of residues forming the protein-protein interface. Therefore, the ligand binding in dimer is impacted not only by the modulating of these key residues, but also by the induced fit binding of ligand. Overall, this analysis shows that the binding of the best compounds on monomeric SARS-CoV2 M pro or SARS-CoV M pro more importantly impacts the ∆G bind value estimated for each ligand due to the conformational changes coupled to the binding, whereas the affinity trends observed for the best compounds on the dimeric systems were not affected.

In this research, we first performed the docking of 15 FDA-approved drugs, which were previously identified as potential inhibitors of monomeric SARS-CoV2 M pro , by employing the recently elucidated crystallographic structure of monomer and dimeric SARS-CoV2 M pro ; then, 100-ns-long MD simulations coupled to the MM/GBSA approach were performed to compare results using both monomeric versus dimeric states, where the latter corresponds to the functional state. Additionally, similar studies were performed, including two known HIV-1 protease inhibitors, lopinavir and ritonavir, which have been previously employed as an effective therapy against SARS-CoV M pro , to compare the inhibitory differences. Our results identified perampanel (best compound), praziquantel (second best compound) and nelfinavir (third best compound) as potential inhibitors of dimeric SARS-CoV2 M pro , and these ligands also showed similar inhibitory properties than those of lopinavir and better inhibitory properties than those of ritonavir. Furthermore, comparative analysis of the affinity of lopinavir and ritonavir on SARS-CoV2 M pro and SARS-CoV M pro revealed that both compounds showed a higher affinity to SARS-CoV2 M pro . On the basis of per-residue free energy decomposition, we identified the hot-spot residues (H41, M49, N142, G143, S144, C145, M165, D187, Q189, T190, A191 and Q192) which contribute significantly high to the total binding affinity. Among these residues H41 and C145 are conserved residues. Therefore, these key residues are important for drug binding. This study demonstrates for the first time that the coupling of ligands on dimeric SARS-CoV2 M pro is linked to differences in the binding affinity in both subunits that may be characteristic of cooperativity. Our study also demonstrates that to obtain more confident drug discovery results, it is better to employ the dimeric state than the monomeric state since ligand binding on the monomer is coupled to conformational changes that contribute to the impact of the ∆G bind value. 

The newly emerged SARS-like coronavirus HCoV-EMC also has an "Achilles' heel": current effective inhibitor targeting a 3C-like protease

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

The PyMOL Molecular Graphics System

Proceedings of the National Academy of Sciences

Trace of the diagonalized covariance matrix of the backbone atoms for free and bound dimeric SARS-CoV2 and SARS-CoV M pro systems System Covariance

Ritonavir bound at subunit 2 (A) of dimeric SARS-CoV2 M pro . Lopinavir coupled at subunits 1 (B) and 2 (C) and ritonavir at subunit 1 (D) of dimeric SARS-CoV M pro

The work was supported by grants from CONACYT (CB-A1-S-21278) and SIP/IPN